The University Medical Center Goettingen (UMG) comprises the University Hospital and the Faculty of Medicine of the Georg- August-University that is one of the six largest faculties of human medicine in Germany. In 2008 a Comprehensive Cancer Center (G-CCC) was established at the UMG-GOE to improve the quality of cancer patient care and to promote basic and clinical research. UMG-GOE comprises an interdisciplinary group of medical doctors, all with high experience in gastrointestinal cancer: Prof Frauke Alves (Translational Molecular Imaging Group, Dept of Haematology and Medical Oncology and Dept of Diagnostic and Interventional Radiology), Prof Lorenz Truemper (Director of G-CCC, Dept of Haematology and Medical Oncology), Prof Philipp Stroebel (Dept of Pathology), Prof Michael Ghadimi (Dept of General, Visceral and Child Surgery) and Prof Volker Ellenrieder (Dept of Gastroenterology and Gastrointestinal Oncology). UME-GOE will provide expertise in tumour-rodent models, non-invasive imaging, tumour pathology and gastrointestinal surgery. UMG-GOE will be responsible in preclinical evaluation of the medical potential of the image guided surgery approach, will test the proposed technology against present surgical and diagnostic approaches and clearly define the scope and clinical potential of the probes for image guided surgery.|
|Staff Expertise||Prof Alves has developed as a clinician a thorough bench to bedside approach in oncology by also leading an interdisciplinary research group in translational molecular imaging research group at the Max-Planck-Institute of Experimental Medicine. She has a long standing experience in evaluating preclinically the efficacy of novel anti-cancer therapies and diagnostic tools by applying imaging technologies in tumour mouse models. As a clinician Prof Ghadimi is treating especially patients with cancer of the gastrointestinal tract throughout his surgical carrier and Prof Stroebel is a specialist in oncologic pathology with a focus on gastrointestinal pathology, mainly colorectal and pancreatic cancer and a strong scientific track record of translational preclinical research. Prof Ellenrieder is highly interested in identification of novel biomarkers and to establish useful endoscopic strategies for improvement of life quality at advanced tumour stages. He has a long standing experience in translational approaches aiming on epigenetics and transcriptional mechanisms in pancreatic cancer development and treatment resistance combining genetically modified pancreatic cancer mouse models with state-of-the-art molecular approaches.|
|Key facilities and infrastructure||• Investigation of tumour progression, angiogenesis, and the optimization and preclinical evaluation of novel anti-tumour therapies and diagnostic tools by applying orthotopiccancer mouse models combined with non-invasive imaging technologies such as SPECT, high resolution Computer Tomography, ultrasound imaging and optical imaging (Optix MX2 and IVIS Spectrum) in combination with fluorescent probes.|
• Further equipment: a luminescence imager, a microCT, an intravitaland advanced fluorescence microscopes.
• State-of-the-Art techniques to study epigenetics and transcriptional mechanisms in mouse and human including ChIP, ChIP-Seq and GSEA analysis.
• Generation and in-depth characterization of transgenic tumour mouse models (e.g. KrasG12D; p53R172H; KrasG12D; c.n.NFATc1; KrasG12D; p53wt/fl; etc)
|Previous involvement in Research Programmes||• 2004 - 2009 EC FP6: THYMAIDE “Novel approaches to pathogenesis, diagnosis and treatment of autoimmune diseases based on new insights into thymus-dependent self-tolerance”.|
• 2006 - 2011 EC FP6: CONTICANET: Connnective Tissue Cancers Network to integrate european experience in adults and children
• 2009 - 2013 EC FP7: IAPP, Public Private Partnership for Asthma Imaging and Genomics (www.p3agi.eu)
• 2006 - 2012: SPP 1190 “The Tumour vessel interface” (http://www.tumorvessel.de) of the German Research Council (Deutsche Forschungsgemeinschaft).
• Transregio TR-17 “Ras signaling in cancer” (German Research Council)
• KFO 210 „Genetics in cancer resistance“ (German Research Council)
• Graduiertenkolleg 1034 „Die Bedeutung genetischer Polymorphismen in der Onkologie: Von den Grundlagen zur individualisierten Therapie“ (German Research Council)
|Current Involvement in Research Programmes||• 2010 – 2014 EC FP7: NAMDIATREAM (www.namdiatream.eu) |
• 2011 – 2015 EC FP7: Marie Curie Training program “Ion Transport Proteins Control Pancreatic Ductal Adenocarcinoma” (www.iontrac.uni-muenster.de)
• 2007 – 2013 EC FP7: Innovabone (www.innovabone.eu)
• 2014 – 2017: Else Kroener-Forschungskolleg Goettingen: „Molekulare Therapie und Prädiktion beim kolorektalen Karzinom“
• 2007 – 2014: Forschergruppe FOR 942 “WNT signalling in development and tumor progression“ (German Research Council)
• 2007 – 2014: Klinische Forschergruppe KFO 179 (www.kfo179.de) „Biological basis of individual tumour response in patients with rectal cancer“ (German Research Council)
|Publications||• Behnke T. et al. Biomaterials (2013) |
• Mathejczyk J.E. et al. J Biomedical Optics (2012)
• Mathejczyk J.E. et al. Mol Imaging (2011)
• Napp J. et al. Anal Chem (2011).
• Napp J. et al. Int. J Cancer (2010)
• Koenig, A. et al.Gastroenterology (2010)
• Baumgart S. et al. Gastroenterology (2012)
• Baumgart S. et al. Cancer Discovery (2014)
• Zhang G. et al. Cancer Res. (2013)
• Sprenger T. et al. Am J SurgPathol. (2013)
• Homayounfar, K., et al. Int J Colorectal Dis. (2013)
• Ebert S. et al. N Engl J Med (2012)
• Schlücker MP. et al. Anal Chem (2011)
• Hildenbrand R. et al. Am J Pathol (2009)
Overview of all participants ...